Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

25-Hydroxyvitamin D3 suppresses hepatitis C virus production.

Matsumura T, Kato T, Sugiyama N, Tasaka-Fujita M, Murayama A, Masaki T, Wakita T, Imawari M.

Hepatology. 2012 Oct;56(4):1231-9. doi: 10.1002/hep.25763.

PMID:
22487892
2.

Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes.

Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, Zemel R.

Hepatology. 2011 Nov;54(5):1570-9. doi: 10.1002/hep.24575.

PMID:
21793032
3.

1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial.

Kondo Y, Kato T, Kimura O, Iwata T, Ninomiya M, Kakazu E, Miura M, Akahane T, Miyazaki Y, Kobayashi T, Ishii M, Kisara N, Sasaki K, Nakayama H, Igarashi T, Obara N, Ueno Y, Morosawa T, Shimosegawa T.

PLoS One. 2013 May 23;8(5):e63672. doi: 10.1371/journal.pone.0063672. Print 2013.

4.

Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis.

Kitson MT, Sarrazin C, Toniutto P, Eslick GD, Roberts SK.

J Hepatol. 2014 Dec;61(6):1247-52. doi: 10.1016/j.jhep.2014.08.004. Epub 2014 Aug 15. Review.

PMID:
25135863
5.

Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways.

Young KC, Bai CH, Su HC, Tsai PJ, Pu CY, Liao CS, Lin YM, Lai HW, Chong LW, Tsai YS, Tsao CW.

Antiviral Res. 2014 Oct;110:158-67. doi: 10.1016/j.antiviral.2014.08.002. Epub 2014 Aug 21.

PMID:
25151487
6.

Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway.

Liu WL, Yang HC, Su WC, Wang CC, Chen HL, Wang HY, Huang WH, Chen DS, Lai MY.

PLoS One. 2012;7(9):e43824. doi: 10.1371/journal.pone.0043824. Epub 2012 Sep 4.

7.

HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).

Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM, Zeuzem S, Schalm SW, von Wagner M, Germanidis G, Lurie Y, Esteban JI, Haagmans BL, Hezode C, Lagging M, Negro F, Homburger Y, Neumann AU, Ferrari C, Missale G; DITTO-HCV Study Group..

Gastroenterology. 2007 Oct;133(4):1132-43. Epub 2007 Jul 3.

PMID:
17919489
8.

Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA.

Kanda T, Yokosuka O, Imazeki F, Tanaka M, Shino Y, Shimada H, Tomonaga T, Nomura F, Nagao K, Ochiai T, Saisho H.

J Viral Hepat. 2004 Nov;11(6):479-87.

PMID:
15500548
9.

Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.

Tanabe Y, Sakamoto N, Enomoto N, Kurosaki M, Ueda E, Maekawa S, Yamashiro T, Nakagawa M, Chen CH, Kanazawa N, Kakinuma S, Watanabe M.

J Infect Dis. 2004 Apr 1;189(7):1129-39. Epub 2004 Mar 16.

PMID:
15031779
10.

Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.

Vispo E, Barreiro P, Rodriguez-Nóvoa S, Morello J, Labarga P, Martín-Carbonero L, Maida I, García-Gascó P, Soriano V.

Antivir Ther. 2008;13(4):511-7.

PMID:
18672529
11.

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.

Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, Milstein SL, Lai MM.

Hepatology. 2003 Oct;38(4):869-78.

PMID:
14512874
12.

Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.

Yano Y, Seo Y, Miki A, Saito M, Kato H, Hamano K, Oya M, Ouchi S, Fujisawa T, Yamada H, Yamashita Y, Tani S, Hirohata S, Yoon S, Kitajima N, Kitagaki K, Kawara A, Nakashima T, Yu H, Maeda T, Azuma T, El-Shamy A, Hotta H, Hayashi Y; Kobe Hepatitis Therapeutic Group..

Int J Mol Med. 2012 Nov;30(5):1048-52. doi: 10.3892/ijmm.2012.1093. Epub 2012 Aug 9.

PMID:
22899224
13.

Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.

Mira JA, Rivero A, de Los Santos-Gil I, López-Cortés LF, Girón-González JA, Márquez M, Merino D, del Mar Viloria M, Téllez F, Ríos-Villegas MJ, Omar M, Rivero-Juárez A, Macías J, Pineda JA; Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)..

AIDS. 2012 Aug 24;26(13):1721-4.

PMID:
22695304
14.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
15.

Inhibitory effect of kaolin minerals compound against hepatitis C virus in Huh-7 cell lines.

Ali L, Idrees M, Ali M, Hussain A, Ur Rehman I, Ali A, Iqbal SA, Kamel EH.

BMC Res Notes. 2014 Apr 17;7:247. doi: 10.1186/1756-0500-7-247.

16.

Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV.

Stevenson NJ, Murphy AG, Bourke NM, Keogh CA, Hegarty JE, O'Farrelly C.

PLoS One. 2011;6(11):e27866. doi: 10.1371/journal.pone.0027866. Epub 2011 Nov 16.

17.

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.

Kneteman NM, Howe AY, Gao T, Lewis J, Pevear D, Lund G, Douglas D, Mercer DF, Tyrrell DL, Immermann F, Chaudhary I, Speth J, Villano SA, O'Connell J, Collett M.

Hepatology. 2009 Mar;49(3):745-52. doi: 10.1002/hep.22717.

PMID:
19072827
18.

Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.

Li S, Kodama EN, Inoue Y, Tani H, Matsuura Y, Zhang J, Tanaka T, Hattori T.

Antivir Chem Chemother. 2010 Aug 11;20(6):239-48. doi: 10.3851/IMP1597.

PMID:
20710064
19.

Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity.

Brochot E, Duverlie G, Castelain S, Morel V, Wychowski C, Dubuisson J, François C.

Antivir Ther. 2007;12(5):805-13.

PMID:
17713164
20.

HCV IRES-mediated core expression in zebrafish.

Zhao Y, Qin W, Zhang JP, Hu ZY, Tong JW, Ding CB, Peng ZG, Zhao LX, Song DQ, Jiang JD.

PLoS One. 2013;8(3):e56985. doi: 10.1371/journal.pone.0056985. Epub 2013 Mar 1.

Supplemental Content

Support Center